AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16461168 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic treatment including high-velocity and low-amplitude manipulation, proprioceptive neuromuscular facilitation, ischemic compression of myofascial trigger points, and spinal rehabilitation exercises.
Number of subjects: 41
Study 16461168 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 41
Study 14767084 — intervention group
Group type: EXPERIMENTAL
Intervention: Desferrioxamine (DFX) at a dose of 40 mg/kg subcutaneously, 5 days/week
Number of subjects: 30
Study 14767084 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral deferiprone (L1) at a dose of 75 mg/kg/day
Number of subjects: 30
Study 14767084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of daily L1 at a dose of 75 mg/kg/day and DFX at a dose of 40 mg/kg/day two times per week
Number of subjects: 30
Study 11577795 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment with gabexate
Number of subjects: 0
Study 11577795 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibacterials (carbapenems and quinolones)
Number of subjects: 0
Study 11577795 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antifungal therapy
Number of subjects: 0
Study 11577795 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy focusing on suppression of pro-inflammatory cytokines
Number of subjects: 0
Study 11577795 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants
Number of subjects: 0
Study 9285295 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN-beta 1b (Betaseron) treatment
Number of subjects: 0
Study 8123056 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation of 35% CO2 and 65% O2 for 30 seconds
Number of subjects: 61
Study 8123056 — intervention group
Group type: COMPARATOR
Intervention: Increased airway resistance (breathing through a valve reducing airway diameter)
Number of subjects: 61
Study 3779921 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary streptokinase (152 patients) or intracoronary streptokinase preceded by intravenous streptokinase (117 patients)
Number of subjects: 533
Study 3779921 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (264 patients)
Number of subjects: 533
Study 30550344 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp50
Number of subjects: 80
Study 30550344 — intervention group
Group type: COMPARATOR
Intervention: BIAsp30
Number of subjects: 80
Study 28124799 — intervention group
Group type: EXPERIMENTAL
Intervention: Social skills training (8 weekly 2-hour sessions including cooperation, assertion, social cognitive problem solving strategies, role playing, games, and arts and crafts)
Number of subjects: 91
Study 28124799 — intervention group
Group type: COMPARATOR
Intervention: Attention placebo control (games and arts and crafts only)
Number of subjects: 91
Study 24720731 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin administration
Number of subjects: 27
Study 24720731 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline) administration
Number of subjects: 27
Study 24347577 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudate-putaminal transplantation of fetal striatal tissue
Number of subjects: 26
Study 24347577 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 26
Study 22151469 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent carotid endarterectomy (within 48 hours)
Number of subjects: 456
Study 22151469 — intervention group
Group type: COMPARATOR
Intervention: Delayed carotid endarterectomy (operated between 48 hours and 15 days after onset of symptoms)
Number of subjects: 456
Study 22151469 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent carotid endarterectomy
Number of subjects: 456
Study 22151469 — intervention group
Group type: COMPARATOR
Intervention: Delayed carotid endarterectomy
Number of subjects: 456
Study 22151469 — intervention group
Group type: EXPERIMENTAL
Intervention: Urgent carotid endarterectomy and Delayed carotid endarterectomy
Number of subjects: 456
Study 19222764 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.4 mg intravenous bolus followed by continuous infusion of 20 microg kg(‐1) h(‐1))
Number of subjects: 18
Study 19222764 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo control)
Number of subjects: 18
Study 17559748 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 22
Study 17559748 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 15337176 — intervention group
Group type: EXPERIMENTAL
Intervention: High laser scan resolution (30,000 laser scan points and more)
Number of subjects: 12
Study 15337176 — intervention group
Group type: EXPERIMENTAL
Intervention: Low laser scan resolution (6000 laser scan points and less)
Number of subjects: 12
Study 11702663 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 polymorphism in recurrence group (n=52)
Number of subjects: 104
Study 11702663 — intervention group
Group type: COMPARATOR
Intervention: NAT2 polymorphism in control group (n=52)
Number of subjects: 104
Study 11702663 — intervention group
Group type: EXPERIMENTAL
Intervention: NAT2 heterogeneity type in recurrence group (n=52)
Number of subjects: 104
Study 11702663 — intervention group
Group type: COMPARATOR
Intervention: NAT2 heterogeneity type in control group (n=52)
Number of subjects: 104
Study 11702663 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type NAT2 (Wt/Wt)
Number of subjects: 104
Study 11702663 — intervention group
Group type: EXPERIMENTAL
Intervention: M*/M* genotype
Number of subjects: 104
Study 8016770 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 500 micrograms four times daily
Number of subjects: 25
Study 8016770 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 1000 micrograms four times daily
Number of subjects: 25
Study 8016770 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled terbutaline 1500 micrograms four times daily
Number of subjects: 25
Study 8016770 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 2659290 — intervention group
Group type: EXPERIMENTAL
Intervention: Aztreonam + Clindamycin
Number of subjects: 156
Study 2659290 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin + Clindamycin
Number of subjects: 156
Study 4938522 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional premedication (pethidine, promethazine, and atropine)
Number of subjects: 70
Study 4938522 — intervention group
Group type: COMPARATOR
Intervention: Neuroleptanalgesia (droperidol and phenoperidine)
Number of subjects: 70
Study 31609072 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocatin B (AvoB) 50 mg per day for 60 days
Number of subjects: 0
Study 31609072 — intervention group
Group type: EXPERIMENTAL
Intervention: Avocatin B (AvoB) 200 mg per day for 60 days
Number of subjects: 0
Study 31609072 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 0
Study 28366507 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured elaborative feedback in clinical dental skills teaching
Number of subjects: 60
Study 28366507 — intervention group
Group type: COMPARATOR
Intervention: Control group (no elaborative feedback)
Number of subjects: 60
Study 28366507 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured elaborative feedback
Number of subjects: 60
Study 25340383 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 1218
Study 25340383 — intervention group
Group type: COMPARATOR
Intervention: Maximal medical therapy
Number of subjects: 1218
Study 25340383 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal medical therapy plus LVRS
Number of subjects: 1218
Study 23595135 — intervention group
Group type: EXPERIMENTAL
Intervention: SYN (synbiotic supplementation)
Number of subjects: 17
Study 23595135 — intervention group
Group type: COMPARATOR
Intervention: PLA (placebo with maltodextrin)
Number of subjects: 17
Study 21380990 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral micronized progesterone (MP) 400 mg
Number of subjects: 33
Study 21380990 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 19343972 — intervention group
Group type: EXPERIMENTAL
Intervention: Microforceps
Number of subjects: 28
Study 19343972 — intervention group
Group type: COMPARATOR
Intervention: Vitrector
Number of subjects: 28
Study 16909322 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse Family Partnership (NFP) home visiting intervention
Number of subjects: 111
Study 12526238 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin holding for 2 hours for 2 consecutive days
Number of subjects: 14
Study 12526238 — intervention group
Group type: COMPARATOR
Intervention: Incubator care
Number of subjects: 14
Study 12526238 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin holding
Number of subjects: 14
Study 10950445 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiking poles (E)
Number of subjects: 20
Study 10950445 — intervention group
Group type: COMPARATOR
Intervention: No hiking poles (C)
Number of subjects: 20
Study 9386146 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol (1 mg sublingual)
Number of subjects: 16
Study 9386146 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sublingual)
Number of subjects: 16
Study 7938102 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone (P) treatment (group 1)
Number of subjects: 56
Study 7938102 — intervention group
Group type: EXPERIMENTAL
Intervention: Early remission with P (group 2a)
Number of subjects: 56
Study 7938102 — intervention group
Group type: EXPERIMENTAL
Intervention: Early remission without P (group 2b)
Number of subjects: 56
Study 7938102 — intervention group
Group type: COMPARATOR
Intervention: Control group (group 3)
Number of subjects: 56
Study 7938102 — intervention group
Group type: EXPERIMENTAL
Intervention: Groups 1 and 2
Number of subjects: 56
Study 3162501 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid contact lenses
Number of subjects: 25
Study 3162501 — intervention group
Group type: COMPARATOR
Intervention: Soft contact lenses
Number of subjects: 25
Study 3162501 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid contact lenses (recovery data)
Number of subjects: 25
Study 29374988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle block after tourniquet inflation with local incisional anesthetic at closure (Group C)
Number of subjects: 0
Study 29374988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle block after tourniquet inflation (Group B)
Number of subjects: 0
Study 29374988 — intervention group
Group type: COMPARATOR
Intervention: Ankle block before tourniquet inflation (Group A)
Number of subjects: 0
Study 29374988 — intervention group
Group type: COMPARATOR
Intervention: Narcotic consumption
Number of subjects: 0
Study 25153307 — intervention group
Group type: EXPERIMENTAL
Intervention: Black Currant Nectar (BCN)
Number of subjects: 16
Study 25153307 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 16
Study 25637323 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg bid)
Number of subjects: 49
Study 25637323 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 24146219 — intervention group
Group type: EXPERIMENTAL
Intervention: liposomal doxorubicin and intravenous rituximab (500 mg/m² twice/cycle) in CODOX-M/IVAC regimen
Number of subjects: 25
Study 21210009 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldspathic porcelain crowns (group 1)
Number of subjects: 33
Study 21210009 — intervention group
Group type: COMPARATOR
Intervention: Glass-infiltrated alumina all-ceramic crowns (group 2)
Number of subjects: 33
Study 21210009 — intervention group
Group type: COMPARATOR
Intervention: Both groups (group 1 and group 2)
Number of subjects: 33
Study 17681303 — intervention group
Group type: EXPERIMENTAL
Intervention: Local injury to the endometrium
Number of subjects: 121
Study 17681303 — intervention group
Group type: COMPARATOR
Intervention: Gene expression analysis
Number of subjects: 121
Study 16256442 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer advisor intervention
Number of subjects: 0
Study 16256442 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced practice nurse (APN) intervention
Number of subjects: 0
Study 16256442 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 14617263 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administration
Number of subjects: 43
Study 14617263 — intervention group
Group type: COMPARATOR
Intervention: Room air
Number of subjects: 43
Study 11037099 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 48
Study 11037099 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentring questions
Number of subjects: 48
Study 11037099 — intervention group
Group type: COMPARATOR
Intervention: Control questions
Number of subjects: 48
Study 9113347 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous (IV) administration of melanotan-I at a dose of 0.16 mg/kg
Number of subjects: 3
Study 9113347 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) administration of melanotan-I at doses from 0.08 to 0.21 mg/kg
Number of subjects: 3
Study 9113347 — intervention group
Group type: COMPARATOR
Intervention: Oral (PO) administration of melanotan-I at a dose of 0.16 mg/kg
Number of subjects: 3
Study 8124289 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise stimulus at 86 dB
Number of subjects: 89
Study 8124289 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise stimulus at 76 dB
Number of subjects: 89
Study 8124289 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise stimulus at 66 dB
Number of subjects: 89
Study 8124289 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise stimulus increased from 66 dB to 86 dB
Number of subjects: 89
Study 8124289 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise stimulus increased from 76 dB to 86 dB
Number of subjects: 89
Study 8124289 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise stimulus decreased from 86 dB
Number of subjects: 89
Study 8124289 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated auditory stimulation
Number of subjects: 89
Study 8124289 — intervention group
Group type: EXPERIMENTAL
Intervention: White noise stimulus
Number of subjects: 89
Study 3325593 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lignocaine
Number of subjects: 0
Study 3325593 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 0
Study 29995186 — intervention group
Group type: EXPERIMENTAL
Intervention: Generic pegylated liposomal doxorubicin (SPIL DXR hydrochloride liposome injection)
Number of subjects: 89
Study 29995186 — intervention group
Group type: COMPARATOR
Intervention: Reference products (Caelyx or Doxil)
Number of subjects: 89
Study 27350226 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin
Number of subjects: 263
Study 27350226 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol
Number of subjects: 263
Study 27350226 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytocin
Number of subjects: 263
Study 25417402 — intervention group
Group type: EXPERIMENTAL
Intervention: Liandouqingmai recipe plus standard treatment for CHD
Number of subjects: 101
Study 25417402 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment only (Control)
Number of subjects: 101
Study 22762964 — intervention group
Group type: EXPERIMENTAL
Intervention: Survey completion
Number of subjects: 0
Study 22762964 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with the patient
Number of subjects: 0
Study 22762964 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 0
Study 22762964 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with care and quality of dying
Number of subjects: 0
Study 20391301 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 9
Study 18831970 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem (10 mg)
Number of subjects: 0
Study 18831970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16896508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate (30 mg daily for 3 days, total 90 mg)
Number of subjects: 32
Study 16896508 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 16896508 — intervention group
Group type: EXPERIMENTAL
Intervention: Pamidronate
Number of subjects: 32
Study 14662571 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-component acellular vaccine
Number of subjects: 667
Study 14662571 — intervention group
Group type: COMPARATOR
Intervention: 5-component pertussis vaccine
Number of subjects: 667
Study 14662571 — intervention group
Group type: COMPARATOR
Intervention: whole cell pertussis vaccine
Number of subjects: 667
Study 14662571 — intervention group
Group type: COMPARATOR
Intervention: diphtheria and tetanus toxoids vaccine alone
Number of subjects: 667
Study 14662571 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-component pertussis vaccine with booster
Number of subjects: 667
Study 14662571 — intervention group
Group type: COMPARATOR
Intervention: any of the vaccines
Number of subjects: 667
Study 10992836 — intervention group
Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 32
Study 10992836 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal mask airway (LMA)
Number of subjects: 32
Study 8995031 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 4 i.u./m2/day for 6 months
Number of subjects: 20
Study 8995031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 1603140 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplementation (1000 mg of calcium citrate malate per day)
Number of subjects: 70
Study 1603140 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 70
Study 3894128 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (pump treatment)
Number of subjects: 65
Study 3894128 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin treatment
Number of subjects: 65
Study 30289489 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative age stereotypes priming
Number of subjects: 114
Study 30289489 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive age stereotypes priming
Number of subjects: 114
Study 30289489 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no priming)
Number of subjects: 114
Study 29664000 — intervention group
Group type: EXPERIMENTAL
Intervention: BPLE‐CPR
Number of subjects: 279
Study 29664000 — intervention group
Group type: COMPARATOR
Intervention: S‐CPR
Number of subjects: 279
Study 26906164 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise (six whole-body exercises, three sets, 8-10 repetitions, 70% 1RM)
Number of subjects: 14
Study 26906164 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (30min cycling, 60% VO2peak)
Number of subjects: 14
Study 26906164 — intervention group
Group type: COMPARATOR
Intervention: Control condition (day prior to exercise)
Number of subjects: 14
Study 24978856 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV‐16/18 AS04‐adjuvanted vaccine
Number of subjects: 505
Study 23707680 — intervention group
Group type: EXPERIMENTAL
Intervention: Active acupuncture
Number of subjects: 101
Study 23707680 — intervention group
Group type: COMPARATOR
Intervention: Placebo acupuncture
Number of subjects: 101
Study 23707680 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived treatment allocation (active vs placebo)
Number of subjects: 101
Study 23707680 — intervention group
Group type: EXPERIMENTAL
Intervention: Expected pain levels
Number of subjects: 101
Study 20713756 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine
Number of subjects: 60
Study 20713756 — intervention group
Group type: COMPARATOR
Intervention: Levocetirizine
Number of subjects: 60
Study 18787890 — intervention group
Group type: EXPERIMENTAL
Intervention: Active suction applied to the underwater seal drainage (group I)
Number of subjects: 91
Study 18787890 — intervention group
Group type: COMPARATOR
Intervention: Simple underwater seal drainage (group II)
Number of subjects: 91
Study 18787890 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study 16438899 — intervention group
Group type: EXPERIMENTAL
Intervention: NPPV
Number of subjects: 342
Study 16438899 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment
Number of subjects: 342
Study 12885807 — intervention group
Group type: EXPERIMENTAL
Intervention: Semimonthly regimen of fluorouracil and leucovorin (LVFU2)
Number of subjects: 905
Study 12885807 — intervention group
Group type: COMPARATOR
Intervention: Monthly regimen of fluorouracil and leucovorin (FULV)
Number of subjects: 905
Study 11475269 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 0.25 mg
Number of subjects: 143
Study 11475269 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 0.5 mg
Number of subjects: 143
Study 11475269 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 1 mg
Number of subjects: 143
Study 11475269 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 2 mg
Number of subjects: 143
Study 11475269 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide 4 mg
Number of subjects: 143
Study 11475269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 8785252 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifabutin
Number of subjects: 1100
Study 8785252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1100
Study 1877851 — intervention group
Group type: EXPERIMENTAL
Intervention: MaxEPA (eicosapentaenoic acid) 20 g daily
Number of subjects: 27
Study 1877851 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (placebo) 20 g daily
Number of subjects: 27
Study 6781613 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestradiol 150 mg
Number of subjects: 0
Study 6781613 — intervention group
Group type: COMPARATOR
Intervention: Prostaglandin E2 (PGE2) 4 mg
Number of subjects: 0
Study 30943184 — intervention group
Group type: COMPARATOR
Intervention: Best conventional scleral lenses
Number of subjects: 10
Study 30943184 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided (WFG) scleral lenses
Number of subjects: 10
Study 28769121 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (60 min treadmill exercise at 59% peak oxygen uptake)
Number of subjects: 47